Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 22, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition via Option Exercise | Ordinary Shares (25 pence each) | £10.13 | 2,042 shares |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records three separate but identical transactions executed on the same date under the Company's ShareSave Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of share acquisitions by the following executives:
- Mr. S. Dingemans (Chief Financial Officer): Acquired 266 shares.
- Mr. N. Hirons (SVP, Global Ethics & Compliance): Acquired 888 shares.
- Mrs. V. Whyte (Company Secretary): Acquired 888 shares.
All transactions involved the exercise of options granted on October 29, 2015, at a price of £10.13 per share, executed on the London Stock Exchange.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs (2,042 shares) against the company's insider trading registry.
- Confirm the option grant date (October 29, 2015) and exercise price (£10.13) align with the ShareSave Plan terms.
- Note that this filing does not reflect the company's broader financial results for the period; refer to Form 20-F for comprehensive financial data.